Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VIR-2482 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| VIR-2482 | EXPERIMENTAL | VIR-2482 |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| VIR-2482 | DRUG | VIR-2482 given by intramuscular injection |
| Placebo | DRUG | Sterile normal saline (0.9% NaCl) given by intramuscular injection |
Inclusion Criteria: * Healthy Male or Female age 18 to \< 65 years * Body mass index (BMI) of 18.0 kg/m\^2 to 32.0kg/m\^2 Exclusion Criteria: * Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation * History of influenza-like illness o...
VIR-2482 is an investigational small molecule being developed for the prevention or treatment of Influenza A. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy in clinical trials.
VIR-2482 is a small molecule designed to target Influenza A. The specific molecular target has not been disclosed, but the drug is being studied for its ability to address Influenza A infections. It is in Phase 1 development by Vir Biotechnology.
VIR-2482 is being developed by Vir Biotechnology, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VIR. The company is conducting clinical research on this investigational drug for Influenza A.
VIR-2482 is in Phase 1 clinical development. It is an investigational drug, meaning it is not yet approved by the FDA or other regulatory agencies. The drug is being studied for Influenza A and has completed one Phase 1 trial.
VIR-2482 has one completed clinical trial, NCT04033406, titled 'Study of VIR-2482 in Healthy Volunteers.' This Phase 1 trial enrolled 100 participants in Australia and was a randomized, double-blind, placebo-controlled study. The trial has been completed, and no active trials are currently listed.
VIR-2482 is not known to have alternative names. It is a unique investigational small molecule developed by Vir Biotechnology for Influenza A. No other names or aliases have been associated with this drug in the available clinical trial information.